Advertisement

Toxizität

  • C. Bokemeyer
  • H.-D. Peters
  • H.-J. Schmoll
  • J. Radermacher
  • C. Schöber
  • R. Kath
  • J. Niedermeyer
  • H. Fabel
  • M. C. Perry
  • T. Cerny
  • J. Weiß
  • J. D. Beck
  • H. G. Dörr
  • W. Meier
  • S. S. Bielack
  • R. Rossi
  • P. Gutjahr
  • U. Schneider
  • O. Buurmann
Chapter
  • 51 Downloads

Literatur

  1. Bennet WM, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DC (1991) Drug prescribing in renal failure, 2nd edn. American College of Physicians. Philadelphia, pp 143Google Scholar
  2. Carmichael DJS (1992) Handling of drugs in kidney disease. In: Cameron S, Davison AM, Grünfeld J-P, Kerr D, Ritz E (eds) Oxford textbook of clinical nephrology. Univ Press, Oxford, pp 175–196Google Scholar
  3. Fer M, McKinney T, Richardson R et al. (1981) Cancer and the kidney: renal complications of neoplasms. Am J Med 71:704–718PubMedCrossRefGoogle Scholar
  4. Garnick MB (1994) Renal and metabolic complications. Kirkwood JM, Lotze MT, Yasko JM (eds) Current cancer therapeutics. Princeton Academic Press, Philadelphia, pp 264–269Google Scholar
  5. Goodman Gilman A, Rall TW, Nies AS, Taylor P (1990) The pharmacological basis of therapeutics, 8th edn. Pergamon, New YorkGoogle Scholar
  6. Patterson WP, Reams GP (1989) Renal and electrolyte abnormalities due to chemotherapy. In: Perry MC (ed) The chemotherapy source book: management of drug toxicity. Wiliams & Wilkins, Baltimore, pp 648–665Google Scholar
  7. Ponticelli C (1992) Oncology and the kidney. In: Cameron S, Davison AM, Grünfeld J-P, Kerr D, Ritz E (eds) Oxford textbook of clinical nephrology. Univ Press, Oxford, pp 2316–2322Google Scholar

Literatur

  1. Allen A (1992) The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529–542PubMedGoogle Scholar
  2. Basser RL, Green MD (1993) Strategies for the prevention of anthracycline cardiotoxicity. Cancer Treat Rev 19:57–77PubMedCrossRefGoogle Scholar
  3. Billingham ME, Mason GW, Bristow MR et al. (1978) Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 62:865–872PubMedGoogle Scholar
  4. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Hassison D (1978) Early anthracycline cardiotoxicity. Am J Med 65:823–832PubMedCrossRefGoogle Scholar
  5. Hawkins MJ, Szoll M (1992) The cardiovascular effects of human recombinant cytokines. In: Muggia FM, Green MD, Speyer JL (eds) Cancer treatment and the heart. John Hopkins Univ Press, Baltimore, pp 296–328Google Scholar
  6. Koning J, Palmer P, Franks CR et al. (1991) Cardioxane-ICRF-187: towards anticancer drug specificity through selective toxicity reduction. Cancer Treat Rev 18:1–19PubMedCrossRefGoogle Scholar
  7. LaBianca R, Beratta G, Cleric M et al. (1982) Cardiac toxicity of 5-fluorouracil: a study of 1083 patients. Tumori 68:505–510PubMedGoogle Scholar
  8. Legha SS, Benjamin RS, Meackay B et al. (1982) Reduction of doxorubicin toxicity by prolonged continous intravenous infusion. Ann Intern Med 96:133–139PubMedGoogle Scholar
  9. Lipschultz SE, Colan SD, Gelber RD et al. (1991) Late effects for doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815CrossRefGoogle Scholar
  10. Olsen RD, Mushin PS (1990) Doxorubicin candiotoxicity: a analysis of prevailing hypotheses. FASEB J 47:359–370Google Scholar
  11. Praga C, Beretta G, Vigo PL et al. (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 62:931–934Google Scholar
  12. Schöber C, Schmoll H-J (1993) Cardiotoxicity associated with 5-fluorouracil single-agent therapy. Onkologie 16:245–251CrossRefGoogle Scholar
  13. Schwartz RG, McKenzie WB, Alexander J et al. (1987) Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven year experience using radionuclide angiocardiography. Am J Med 82:1109–1118PubMedCrossRefGoogle Scholar
  14. Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med 105:67–81PubMedGoogle Scholar
  15. Speyer JL, Green MD, Kramer E et al. (1988) Protective effect of the bispiperazine-dione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745–752PubMedCrossRefGoogle Scholar
  16. Steinherz LJ, Steinherz PG (1985) Cyclophosphamide cardiotoxicity. Cancer Bull 38:231Google Scholar
  17. Torti FM, Howes AE et al. (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: Assessment by endomyocardial biopsy. Ann Intern Med 99:745–749PubMedGoogle Scholar
  18. Verweij J, Funke-Kupper AJ, Teule GJJ et al. (1988) A prospective study on the dose dependency of cardiotoxicity induced by mitomycin-C. Med Oncol Tumor Pharmacother 5:159–163PubMedGoogle Scholar
  19. Villani F, Galimberti M, Comazzi R, Crippa F (1989) Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Clin Oncol 25:13–18CrossRefGoogle Scholar
  20. Vorobiof DA, Iturralde M, Falkson G (1985) Assessment of ventricular function by radionuclide angiography in patients receiving 4’-epidoxorubicin and mitoxantrone. Cancer Chemother Pharmacol 15:253–257PubMedCrossRefGoogle Scholar
  21. Weiss RB, Grillo-Lopez AJ, Marsoni S et al. (1986) Amsacrine-associated cardiotoxicity: an analysis of 82 patients. J Clin Oncol 4:918–928PubMedGoogle Scholar

Literatur

  1. Apfel SC, Arezzo JC, Lipson L, Kessler JA (1992) Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 31(1): 76–80PubMedCrossRefGoogle Scholar
  2. Bokemeyer C, Frank B, van Rhee J, Berger C, Schmoll H-J (1993) Peripheral neuropathy following cancer chemotherapy. Tumordiagn Ther 14:232–237Google Scholar
  3. Hamers FPT, van der Hoop RG, Traber J, Neijt JP, Jennekens FGIO, Gispen WH (1990) The calcium antagonist nimodipine in cisplatin induced neuropathy in the rat. Eur J Pharmacol 183:1710–1711CrossRefGoogle Scholar
  4. Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 9:103–130PubMedGoogle Scholar
  5. Mollman JE, Glover DJ, Hogan WM, Furman RE (1988) Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61(11):2192–5PubMedCrossRefGoogle Scholar
  6. Van der Hoop RG, Vecht CJ, van der Burg MLE, Elderson A, Boogerd W, Heimans JJ, Vries EP, van Houwellingen CJ, Jennekens FGI, Gispen WH, Neijt JP (1990) Prevention of cisplatin neurotoxicity with an ACTH(4–9) analogue in patients with ovarian cancer [see comments]. N Engl J Med 322(2): 89–94PubMedCrossRefGoogle Scholar

Literatur

  1. Basser RL, Green MD (1994) Pulmonary toxicities. In: Kirkwood JM, Lotze MT, Yasko JM (eds) Current cancer therapeutics. Current Medicine, Philadelphia, pp 272–278Google Scholar
  2. Cooper JAD Jr, White DA, Matthay RA (1986) Drug-induced pulmonary disease, part 1: Cytotoxic drugs. Am Rev Respir Dis 133:321–40PubMedGoogle Scholar
  3. Eschenbruch CM (im Druck) Interstitielle Lungenerkrankungen. In: Fabel H (Hrsg) Pneumologie, 2. Aufl. Urban & Schwarzenberg, MünchenGoogle Scholar
  4. Kreisman H, Wolkove N (1992) Pulmonary toxicity of antineoplastic therapy. In: Perry MC (ed) The chemotherapy source book. Williams & Wilkins, Baltimore, pp 598–619Google Scholar
  5. Rosenow III EC (1994) Drug-induced pulmonary disease. In: Murray JF, Nadel JA (eds) Textbook of respiratory medicine, 2nd edn. Saunders, Philadelphia, pp 2117–2144Google Scholar
  6. Rosenow III EC, Meyers JL, Swensen SJ, Pisani RJ (1992) Drug-induced pulmonary disease. An update. Chest 102:239–250PubMedCrossRefGoogle Scholar

Literatur

  1. Adrian R, Hood A, Skarin A (1980) Mucocutaneous reactions to antineoplastic agents. CA-Cancer J Clin 30:143–157PubMedCrossRefGoogle Scholar
  2. Bronner A, Hood A (1983) Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol 9:646–466CrossRefGoogle Scholar
  3. Conrad K, Dexter L (1990) Cutaneous reactions related to treatment with BRM’s. In: Yakso J, Dudjak L (eds) Biological resonanse modifier therapy — symptom management. Cetus, Emeryvill, pp 129–134Google Scholar
  4. Seraly MP, Rhiodes AR (1994) Cutaneous manifestations. In: Kirkwood JM, Lotze MT, Yasko JM (ed) Current cancer therapeutics. Current Medicine, Philadelphia, pp 298–307Google Scholar

Literatur

  1. Bokemeyer C, Scholtissek M, Schmoll H-J, Poliwoda H (1992) Anaphylactoid type reaction in a patient receiving high-dose methotrexate chemotherapy. Onkologie 15:313–316CrossRefGoogle Scholar
  2. Cleare MJ, Hughes EG, Jaxoby B, Pepys J (1976) Immediate (type I) allergic responses to platinum compounds. Clin Allergy 6:183–195PubMedCrossRefGoogle Scholar
  3. Evans WE, Tsiatis A, Rivera G et al. (1982) Anaphylactoid reactions to Escherichia coli and Erwinia asparginase in children with leukemia and lymphoma. Cancer 49:1378–1383PubMedCrossRefGoogle Scholar
  4. Kritharides L, Lawrie K, Varigos GA (1987) Cyclophosphamide hypersensitivity and cross-reactivity with chlorambucil. Cancer Treat Rep 71:1323–1324PubMedGoogle Scholar
  5. Ogle KM, Kennedy BJ (1988) Hypersensitivity reactions to etoposide. A case report and review of the literature. Am J Clin Oncol 11:663–665PubMedCrossRefGoogle Scholar
  6. Solimando DA, Wilson JP (1984) Doxorubicin-induced hypersensitivity reactions. Drug Intell Clin Pharm 18:808–811PubMedGoogle Scholar

Literatur

  1. Gandara D, Perez E, Wiebe V, De Gregorio M (1991) Chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol 18 (1) [Suppl 3]: 49–55PubMedGoogle Scholar
  2. Goel R, Cleary SM, Horton C, Kimani S, Abramson I, Kelly C, Howell SB (1989) Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 81:1552–1560PubMedCrossRefGoogle Scholar
  3. Shaw IC, Graham MI (1987) Mesna-a short review. Cancer Treat Rev 14:47–86Google Scholar
  4. Speyer JL, Green MD, Zieniuch, Jacpuotte A. et al. (1992) ICRF-187 permits a longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117–127PubMedGoogle Scholar

Literatur

  1. Berthelsen JG (1984) Sperm counts and serum follicle-stimulating hormone levels before and after radiotherapy and chemotherapy in men with testicular germ cell cancer. Fertil Steril 4:281–286Google Scholar
  2. Bokemeyer C, Schmoll H-J, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H (1994) Long-term gonadal toxicity after therapy for Hodgkin’s and non- Hodgkin’s lymphoma. Ann Hermatol 68:105–110CrossRefGoogle Scholar
  3. Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U (1977) The CMF program for operable breast cancer with positive axillary nodes. Cancer 39:2904–2915PubMedCrossRefGoogle Scholar
  4. Canellos GP, Anderson JR, Propert KJ et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med 327:1478–1484PubMedCrossRefGoogle Scholar
  5. Chapman RM (1982) Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 9:84–94PubMedGoogle Scholar
  6. Chapman RM, Sutcliff SB (1981) Protection of overian function by oral contraceptives in woman receiving chemotherapy for Hodgkin’s disease. Blood 58:849–851PubMedGoogle Scholar
  7. Choo YC, Chan SYW, Wong LC, Ho K (1985) Ovarian dysfunction in patients with gestational trophoblastic neoplasia with short intensive courses of Etoposide. Cancer 55:2348–2352PubMedCrossRefGoogle Scholar
  8. Cunningham J, Mauch P, Rosenthal DS, Canellos G (1982) Long-term complications of MOPP chemotherapy in patients with Hodgkin’s disease. Cancer Treat Rep 66:1015–1022PubMedGoogle Scholar
  9. Da Cunha MF, Meistrich ML, Fuller LM et al. (1984) Recovery of spermatogenesis after treatment for Hodgkin’s disease: Limiting dose of MOPP chemotherapy. J Clin Oncol 2:571–577PubMedGoogle Scholar
  10. Drasga RE, Einhorn LH, Williams SD, Patel DN, Stevens EE (1983) Fertility after chemotherapy for testicular cancer. J Clin Oncol 1:179–183PubMedGoogle Scholar
  11. Evenson DP, Arlin Z, Welt S, Claps ML, Melamed MR (1984) Male reproductive capacity may recover following drug treatment with the L-10-Protocol for acute lymphocytic leukemia. Cancer 53:30–36PubMedCrossRefGoogle Scholar
  12. Fugger EF, Bustillo M, Dorfmann AD et al. (1991) Human preimplantation embryo cryopeservation — selected aspects. Hum Reprod 6:131–135PubMedGoogle Scholar
  13. Hansen PV, Hansen SW (1993) Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy. Eur Urol 23:153–156PubMedGoogle Scholar
  14. Horning SJ, Hoppe RT, Kalan HS, Rosenberg SA (1981) Fermale reproductive potential after treatment of Hodgkin’s disease. N Engl J Med 304:1377–1382PubMedCrossRefGoogle Scholar
  15. Johnson DH, Hainsworth JD, Linde RB, Greco FA (1984) Testicular function following combination chemotherapy with cisplatin, vinblastine and beomyc-in. Med Pediatr Oncol 12:233–238PubMedCrossRefGoogle Scholar
  16. Kreuser ED, Felsenberg D, Behles C et al. (1992) Long term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin’s disease. Ann Oncol 3 [Suppl 4]: 105–110PubMedGoogle Scholar
  17. LeFloch O, Donaldson SS, Kaplan HS (1976) Pregnancy following oophoropexie and total nodal irradiation in women with Hodgkin’s disease. Cancer 38:2263–2268CrossRefGoogle Scholar
  18. Mancini RE, Lavieri JC, Muller F, Andrada JA, Saraceni DJ (1966) Effect of prednisolone upon normal and pathologic human spermatogenesis. Fertil Steril 17:500–513PubMedGoogle Scholar
  19. Matus-Ridley M, Nicosia SV, Meadows AT (1985) Gonadal effects of cancer therapy in boys. Cancer 55:2353–2363PubMedCrossRefGoogle Scholar
  20. Myers SE, Schilsky RL (1992) Prospects for fertility after cancer chemotherapy. Semin Oncol 19:597–604PubMedGoogle Scholar
  21. Nicosia SV, Matus-Ridley M, Meadows AT (1985) Gonadal effects of cancer therapy in girls. Cancer 55:2364–2372PubMedCrossRefGoogle Scholar
  22. Petersen PM, Hansen SW, Giwercman A, Rorth M, Skakkebaek NE (1994) Dose-dependent impairmant of testicular function in patients treated with cisplatin- based chemotherapy for germ cell cancer. Ann Oncol 5:355–358PubMedGoogle Scholar
  23. Propping D, Katzorke T, Weißbach L (1985) Samenkryokonservierung als Fertilitätsprophylaxe bei urologischen Tumorpatienten. Aktuel Urol 16:20–23CrossRefGoogle Scholar
  24. Rustin GJS (1983) Follow-up, fertility and second tumours. Clin Oncol 2:267–279Google Scholar
  25. Sanger WG, Armitage JO, Schmidt MA (1980) Feasibility of semen cryopreservation in patients with malignant disease. JAMA 244:789–790PubMedCrossRefGoogle Scholar
  26. Schilsky RL (1989) Male fertility following cancer chemotherapy. J Clin Oncol 7:295–297PubMedGoogle Scholar
  27. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT (1981) Long-term follow-up of ovarian function in woman treated with MOPP chemotherapy for Hodgkin’s disease. Am J Med 71:552–556PubMedCrossRefGoogle Scholar
  28. Schmoll HJ, Weiß J (1985) Gonadendysfunktion nach antineoplastischer Therapie. In: König H (Hrsg) Aktuelle Therapie maligner Tumoren, Zuckschwerdt, MünchenGoogle Scholar
  29. Shalet SM (1993) Effect of irradation treatment on gonadal function in men treated for germ cell cancer. Eur Urol 23:148–151PubMedGoogle Scholar
  30. Shamberger RC, Rosenberg SA, Seipp CA, Sherins RJ (1981) Effects of high-dose methotrexate and vincristine on ovarian and testicular function in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep 65:739–746PubMedGoogle Scholar
  31. Smith JA, Urry RL (1985) Testicular histology after prolonged treatment with a gonadotropinreleasing hormone analogue. J Urol 133:612–613PubMedGoogle Scholar
  32. Vigersky RA, Chapman RM, Berenberg J, Glass AR (1982) Testicular dysfunction in untreated Hodgkin’s disease. Am J Med 73:482–486PubMedCrossRefGoogle Scholar
  33. Viviani S, Santoro A, Ragni G, Bonifante V, Bestetti O, Bonadonna G (1985) Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601–605PubMedCrossRefGoogle Scholar
  34. Waxmann JHX, Terry YA, Wrigley PEM et al. (1982) Gonadal function in Hodgkin’s disease: long-term follow-up of chemotherapy. Br Med J 285:1612–1613CrossRefGoogle Scholar
  35. Whitehaead E, Shalet SM, Blackledge G, Todd J, Crowther D, Beardwell CG (1982) The effects of Hodgkin’s disease and combination chemotherapy on gonadal function in adult male. Chancer 49:418–422CrossRefGoogle Scholar

Literatur

  1. Bolag W (1954) Cytostatika in der Schwangerschaft. Schweiz Med Wochenschr 84:393–395Google Scholar
  2. Caligiury M, Mayer RJ (1989) Pregnancy and leukemia. Sem Oncol 16:388–396Google Scholar
  3. Holmes GE, Holmes FF (1978) Pregnancy autcome of patients treated for Hodgkin’s disease. Cancer 41:1317–1322PubMedCrossRefGoogle Scholar
  4. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA (1981) Female reproductive potential after treatment for Hodgkin’s disease. N Engl J Med 304:1377–1382PubMedCrossRefGoogle Scholar
  5. McKeen EA, Mulvihill JJ, Rosner F, Zabarri MH (1979) Pregnancy outcome in Hodgkin’s disease. Lancet 11:590CrossRefGoogle Scholar
  6. Nicholson HO (1968) Cytotoxic drugs in pregnancy. J Obstet Gyn Br Commonw 75:307–312CrossRefGoogle Scholar
  7. Rister M, Müller AM, Gladtke E (1983) Kinder ehemaliger krebskranker Patienten. Dtsch Med Wochenschr 108:1137–1142PubMedCrossRefGoogle Scholar
  8. Ross GT (1976) Congenital anomalies among children born of mothers receiving chemotherapy for gestational trophoblastic neoplasma. Cancer 37:1043–1047PubMedCrossRefGoogle Scholar
  9. Russel JA, Powels RC, Oliver RTD (1976) Conception and congenital abnormalities after chemotherapy of acute myelogenous leukaemia in two men. B Med J 1:1508CrossRefGoogle Scholar
  10. Rustin GYS, Both M, Dent J, Salt S, Rustin F, Bagshawe KD (1984) Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. B Med J 288:103–106CrossRefGoogle Scholar
  11. Schapira DV, Chudley AE (1984) Sucessful pregnancy following continous treatment with combinaiton chemotherapy before conception and throughout pregnancy. Cancer 54:800–803PubMedCrossRefGoogle Scholar
  12. Senturia YD, Peckham CS (1990) Children fathered by men treated with chemotherapy for testicular cancer. Eur J Cancer 26:429–432PubMedCrossRefGoogle Scholar
  13. Sieber SM, Adamson RH (1975) Toxicity of antineoplastic agents in man: hromosomal aberrations, antifertility effects, congenital malformations and arcinogenic potential. Adv Cancer Res 22:57–155PubMedCrossRefGoogle Scholar
  14. Thurber WA (1989) Offspring of childhood cancer survivors. J Assoc Pediatr Oncol Nurses 6:17–19PubMedCrossRefGoogle Scholar
  15. Van Le L, Pizzuti DJ, Greenberg M, Reid R (1991) Accidental use follow-dose 5-fluorouracil in pregnancy. J Reprod Med 36:872–874PubMedGoogle Scholar

Literatur

  1. Berk PD, Goldberg JD, Silverstein MN et al. (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441–447PubMedCrossRefGoogle Scholar
  2. Boice JD, Greene MH, Killen JY et al. (1983) Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309:1079–1984PubMedCrossRefGoogle Scholar
  3. Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11:1703–1709PubMedGoogle Scholar
  4. Bokemeyer C, Liier M, Schmoll HJ, Freund M (1993) Secondary cancer following Hodgkin’s disease. Ann Oncol 4:520–522PubMedGoogle Scholar
  5. Bokemeyer C, Schmoll HJ, Poliwoda H (1994) Sekundäre Leukämien nach Etoposid-haltiger Chemotherapie. Dtsch Med Wochenschr 119:707–713PubMedCrossRefGoogle Scholar
  6. Coltman CA, Dixon DO (1982) Second malignancies complicating Hodgkin’s disease: A Southwest Oncology Group 10-year follow-up. Cancer Treat Rep 66:1023–1033PubMedGoogle Scholar
  7. Fairchild WV, Spence CR, Solomon HD, Gangai MP (1979) The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122:163–164PubMedGoogle Scholar
  8. Gomez GA, Friedman M, Reese P (1983) Occurrence of acute nonlymphocytic leukemia in a prospective randomized study of treatment for Hodgkin’s disease. Am J Clin Oncol 6:319–324PubMedCrossRefGoogle Scholar
  9. Greene MH, Hoover RN, Fraumeni JF Jr (1978) Subsequent cancer in patients with chronic lymphocytic leukemia — a possible immunologic mechnism. J Natl Cancer Inst 61:337–340PubMedGoogle Scholar
  10. Greene MH, Boice JD, Greer BE, Blessing JA, Dembo AJ (1982) Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med 307:1416–1421PubMedCrossRefGoogle Scholar
  11. Henry-Amar M, Dietrich PY (1993) Acute leukemia after the treatment of Hodgkin’s disease. Hematol Oncol Clin N Am 7 (2): 368–387Google Scholar
  12. Jacquillat C, Khayat D, Desprez-Curey JP et al. (1984) Non-Hodgkin’s lymphoma occurring after Hodgkin’s disease. Cancer 53:459–462PubMedCrossRefGoogle Scholar
  13. Kaldor JM, Day NE, Band P et al. (1987) Second malignancies following testicular cancer, ovarian cancer and Hodgkin’s disease: An international collaborative study among cancer registries. Int J Cancer 39:571–585PubMedCrossRefGoogle Scholar
  14. Kaldor JM, Day NE, Clarke A et al. (1990 a) Leukemia following Hodgkin’s disease. N Engl J Med 322:7:13Google Scholar
  15. Kaldor JM, Day NE, Pettersson F (1990 b) Leukemia following chemotherapy for ovarian cancer. N Engl J Med 322:1–6PubMedCrossRefGoogle Scholar
  16. LeBeau MM, Albain KS, Larson RA et al. (1986) Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia. J Clin Oncol 4:325–245Google Scholar
  17. Malkin D, Jolly KW, Barbier N et al. (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326:1309–1315PubMedCrossRefGoogle Scholar
  18. Nelson DF, Cooper S, Weston M, Rubin P (1981) Second malignant neoplasms in patients treated for Hodgkin’s disease with radiotherapy or radiotherapy and chemotherapy. Cancer 48:2286–2393Google Scholar
  19. Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH (1993) Secondary leukemia associated with a conventional dose of etoposide. J Natl Cancer Inst 85:36–40PubMedCrossRefGoogle Scholar
  20. Palmer RG, Dore CJ, Denman AM (1984) Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet 1:246–249PubMedCrossRefGoogle Scholar
  21. Pedersen-Bjergaard J, Nissen NI, Sorensen HM et al. (1980) Acute nonlymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (=Dihydroxybusulfan). Cancer 45:19–29PubMedCrossRefGoogle Scholar
  22. Pedersen-Bjergaard J, Philip P, Pedersen NT, Hou-Jensen K, Svejgaard A, Jensen G, Nissen N (1984) Acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Cancer 54:452–462PubMedCrossRefGoogle Scholar
  23. Pedersen-Bjeergaard J, Philip P, Larson SO, Jensen G, Bryting K (1990) Chromosome abberations and prognostic factors in therapy related myelodysplasia and acute nonlymphocytic leukemia. Blood 6:1083–1091Google Scholar
  24. Penn I (1982) The occurrence of cancer in immune deficiences. Curr Probl Cancer 6 (10): 1–64PubMedCrossRefGoogle Scholar
  25. Penn I (1993) Tumors after renal and cardiac transplantation. Hematol Oncol Clin N Am 7(2):431–445Google Scholar
  26. Portugal MA, Falkson HC, Stevens K, Falkson G (1979) Acute leukemia as a complication of long term treatment of advanced breast cancer. Cancer Treat Rep 63:177–181PubMedGoogle Scholar
  27. Pui CH, Raul MD, Ribeiro C et al (1991) Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682–1687PubMedCrossRefGoogle Scholar
  28. Smith MA, Rubinstein L, Cazenave L et al. (1993) Report of the cancer therapy evaluation program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins. J Natl Cancer Inst 85:554–558PubMedCrossRefGoogle Scholar
  29. Stott H, Fox W, Girling DJ, Stephens RJ, Galton DAG (1977) Acute leukemia after busulphan. Br Med J 2:1513.1517CrossRefGoogle Scholar
  30. Tester WJ, Kinsella TJ, Waller B, Makuch RW, Kelley PA, Glastein E, De Vita VT (1984) Second malignant neoplasms complicating Hodgkin’s disease: The National Cancer Institute experience. J Clin Oncol 2:762–769PubMedGoogle Scholar
  31. Tucker MA (1993) Solid second cancers following Hodgkin’s disease. Hematol Oncol Clin N Am 7 (2):389–415Google Scholar
  32. Valagussa P, Santoro A, Fossati Bellani F, Franchi F, Banfi A, Bonadonna G (1982) Absence of treatment-induced second neoplasms after ABVD in Hodgkin’s disease. Blood 59:488–494PubMedGoogle Scholar
  33. Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebaut AW et al. (1993) Second cancer risk following testicular cancer. J Clin Oncol 11:415–424PubMedGoogle Scholar
  34. Whitlock JA, Greer JP, Lukas JN (1991) Epipodophyllotoxin-related leukemia. Cancer 68:600–604PubMedCrossRefGoogle Scholar

Literatur

  1. Beck JD (1990/91) Spätfolgen der Therapie maligner Erkrankungen im Kindesalter. In: Bundesärztekammer (Hrsg) Fortschritte und Fortbildung in der Medizin, Bd 14Google Scholar
  2. Beck JD, Meier W, Hertzberg H, Überall MA, Berger-Jones K, Brandi U, Huk WJ, Korinthenberg R, Tolks U, Wenzel D, Beck JD (1994) CNS-late effects after ALL-therapy in childhood. Med Ped Oncol 23:259Google Scholar
  3. Beck JD, Winkler K, Niethammer D, Brandis M, Hertzberg H, von der Hardt K, Greil J, Überall MA, Rossi R, Lamprecht-Dinnesen A, Brämswig J, Kaatsch P, Michaelis J, Meier W, Hausdorf G, Bielack S, Dörr HG (1995) Die Nachsorge der von einer Krebserkrankung geheilten Kinder und jungen Erwachsenen. Erste Empfehlungen der Arbeitsgemeinschaft Spätfolgen. Klin Pädiatr 207:186–192PubMedCrossRefGoogle Scholar
  4. Bielack S, Erttmann R, Winkler K, Landbeck G (1989) Doxorubicin: Effect of different schedules on toxicity and antitumor efficacy. Eur J Cancer Clin Oncol 25:873–883PubMedCrossRefGoogle Scholar
  5. Billingham ME, Masek M (1993) The pathology of antracycline cardiotoxicity in children, adolescents and adults In: Bricker JT, Green DM, D’Angio DJ (eds) Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York Chichester Brisbane Toronto Singapore, pp 17–24Google Scholar
  6. Boivina JF, Hutchison GB, Lubin JH, Mauch P (1992) Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer 69:1241–1247CrossRefGoogle Scholar
  7. Brämswig JH, Korinthenberg R, Gutjahr P (1986) Late effects of antineoplastic chemo-and radiotherapy on the gonads, the nervous system and the occurence of second malignancies. In: Riehm H (ed) Malignant neoplasias in childhood and adolescence. Karger, Basel München Paris London New York New-Delhi Singapore Tokyo Sydney, pp 84–97Google Scholar
  8. Brandis M (1989) 2. Sitzung der Studienkommissionen der Gesellschaft für Pädiatrische Onkologie und der Deutschen Arbeitsgemeinschaft für Leukämieforschung und Behandlung im Kindesalter, Bad Nauheim, MaiGoogle Scholar
  9. Brandi U, Meier W, Wenzel D, Beck JD (1989) Neurologische, neurophysiologi-sche und psychodiagnostische Befunde bei 27 ehemaligen Hirntumorpatienten. 85. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde, Ulm, SeptemberGoogle Scholar
  10. Dopfer RE, Ranke MB (1994) Betreuung von Kindern und Jugenlichen nach Knochenmarktransplantationen. Monographie. Haller, FürthGoogle Scholar
  11. Dowell RE, Copeland DR (1987) Cerebral pathology and neuropsychological effects. Differential effects of cranial radiation as a function of age. Am J Pediatr Hematol Oncol. 9:68–72PubMedCrossRefGoogle Scholar
  12. Estrem SA, Babin RW, Ryn JH, Moore KG (1981) Cis-diamminodichloroplati-num (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 89:638–645PubMedGoogle Scholar
  13. Fajardo LF (1992) Pathology of radiation-induced herart disease. In: Bricker JT, Green DM, D’Angio GJ (eds) Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York Chichester Brisbane Toronto Singapore, pp 7–16Google Scholar
  14. Gutjahr P (1993) Sekundärmalignome nach Krebserkrankungen bei Kindern. Dtsch Ärztebl 21 A: 1593–1604Google Scholar
  15. Hancock SL, Donaldson SS, Happe RT (1993) Cardiac disease following treatment of Hodgkin’s disease in children and adolescents J Clin Oncol 11:1208–1215PubMedGoogle Scholar
  16. Harten G, Stephanie U, Henze G, Langermann H-J, Riehm H, Hanefeld F (1984) Slight impairment of psychomotoric skills in children after treatment of acute lymphoblastic leukemia. Eur J Pediatr 142:189–197PubMedCrossRefGoogle Scholar
  17. Hausdorf G (1993) Late effects of anthracycline therapy in childhood: evaluation and current therapy In: Bricker JT, Green DM, D’Angio GJ (eds) Cardiac toxicity after treatment for childhood cancer. Wiley-Liss, New York Chichester Brisbane Toronto Singapore, pp 73–85Google Scholar
  18. Hausdorf G, Morf G, Beron G, Erttmann R, Winkler K, Landbeck G, Keck EW (1988) Long term doxorubicin cardiotoxitiy in childhood: noninvasive evaluation of the contractile state and diastolic filling. Br Heart J 60:309–315PubMedCrossRefGoogle Scholar
  19. Hawkins MM, Draper GJ, Kingston JE (1987) Incidence of second primary tumours among childhood cancer survivors Br. J Cancer 86:339–347CrossRefGoogle Scholar
  20. Hertzberg H, Meier W, Berger K, Korinthenberg R, Tolks U, Wenzel D, Beck JD (1994) CNS-late effects after ALL-therapy in childhood. 3rd International Conference on the Long-Term Complications of Treatment of Children and Adolescents for Cancer. Niagara Falls, New York, JuneGoogle Scholar
  21. Hertzberg H, Huk WJ, Überall MA, Langer Th, Meier W, Dopfer R, Skalej M, Lackner H, Bode U, Janßen G, Zintl F, Beck JD for the German late sequelae working group. Neuroradiological findings and neuropsychological performance in 118 children treated for acute lymphoblastic leukemia with different regimens of central nervous system prophylaxis: Results of a German-Austrian multicenter study. Zur Publikation eingereichtGoogle Scholar
  22. Hoff DD von, Layard M, Basa P (1979) Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91:710–717Google Scholar
  23. Kaatsch P, Michaelis J (1995) Zweimalignome nach malignen Erkrankungen im Kindesalter. Klin Pädiatr 207:158–163PubMedCrossRefGoogle Scholar
  24. Koch A, Beyer R, Erhardt J, Beck JD, Sauer R, Fahlbusch R, Böhles HJ, Dörr HG (1993) Endokrinologische Probleme bei Patienten mit Medulloblastom (MB): Notwendigkeit einer konsequenten Nachsorge. Kinderheilkunde [Suppl 1] 141:48Google Scholar
  25. Li FP (1977) Second malignant tumors after cancer in childhood. Cancer 40:1899–1902PubMedCrossRefGoogle Scholar
  26. Lipschultz SE, Colan S, Gelber R, Perez-Atayde A, Sanders, S (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808–815CrossRefGoogle Scholar
  27. Meadows AT, Baum E, Fossali, Bellani F (1985) Second malignant neoplasms in children: an up take from the late Effects Study Group. J Clin Oncol 3:532–538PubMedGoogle Scholar
  28. Ochs J, Mulhern RK (1992) Prospective evaluation of neuropsychological function following cranial irradiation and intermediate dose Methotrexate. In: Green DM, D’Angio GJ (eds) Late effects of treatment for childhood cancer. Wiley-Liss, New York Chichester Brisbane Toronto Singapore, pp 23–30Google Scholar
  29. O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattamaneni HR, Woodcock AA (1990) Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 323:378–382PubMedCrossRefGoogle Scholar
  30. Rossi R, Kleinebrand A, Gödde A, Rath B, Jürgens (1993) Increased risk of ifosfamide-induced renal Fanconi’s syndrome after unilateral nephrectomy. Lancet 341:755PubMedCrossRefGoogle Scholar
  31. Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H (1994) Unilateral nephrectomy and cisplatinum as risk factors of ifosfamide-indused nephrotoxisity: Analysis of 120 patients. J Clin Oncol 12:159–165PubMedGoogle Scholar
  32. Schönau E, Hiller B, Scheubel R, Herbst M, Glöckel U, Schrell U, Beck JD (1989) Zeitlicher Verlauf des Wachstums und der Wachstumshormonstimulation behandelter Hirntumorpatienten. 85. Jahrestagung der Deutschen Gesellschaft für Kinderheilkunde Ulm, SeptemberGoogle Scholar
  33. Shalet SM, Clayton PE, Price DA (1988) Growth impairment following treatment for childhood brain tumors. Acta Pediatr Scand [Suppl] 343:137–145Google Scholar
  34. Show NJ, Piveddale PM, Eden DB (1989) Pulmonary function in childhood leukemia survivors. Med Pediatr Oncol 17:149–154CrossRefGoogle Scholar
  35. Steinherz LJ, Steinherz PG, Mangiacasale D, O’Reilly R, Jallen J, Sorell M, Miller DR (1981) Cardiac changes with cyclophosphamide Med Pediatr Oncol 9:417–422PubMedCrossRefGoogle Scholar
  36. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study groupe. Pediatrics 89:942–949PubMedGoogle Scholar
  37. Stevens CG, Brandis M (1993) Incidence and etiology of ifosfamide nephrotoxicity: Report of a meeting held in rhodes, greece, October 3. Med Pediatr Oncol 21:640–644PubMedCrossRefGoogle Scholar
  38. Überall MA, Meier W, Hertzberg H, Berger K, Korinthenberg R, Dunst D, Wenzel D, Kühl J, Beck JD (1993) ZNS-Spätfolgen nach ALL-Behandlung: Auswirkungen der ZNS-Prophylaxe. Z Kinderheilk [Suppl 1] 141:48Google Scholar

Literatur

  1. Ng SC, Bongso A, Ratnam SS, Sathananthan AH, Chan CLK, Wong PC et al. (1988) Pregnancy after transfer of sperm under the zona. Lancet 11:790CrossRefGoogle Scholar
  2. Van Streiteghem AC, Nagy Z, Joris H, Liu J, Staessen C, Smitz J, Wisanto A, Devroey P (1993) High fertilization and implantation rates after intracytoplas-mic sperm injection. Hum Reprod 8–77:1061–1066Google Scholar
  3. WHO-Laborhandbuch zur Untersuchung des menschlichen Ejakulates und der Spermatozoen-Zervikalschleim-Interaktion, 3. Aufl. Springer, Berlin Heidelberg New York TokyoGoogle Scholar

Copyright information

© Springer-Verlag Heidelberg 1996

Authors and Affiliations

  • C. Bokemeyer
  • H.-D. Peters
  • H.-J. Schmoll
  • J. Radermacher
  • C. Schöber
  • R. Kath
  • J. Niedermeyer
  • H. Fabel
  • M. C. Perry
  • T. Cerny
  • J. Weiß
  • J. D. Beck
  • H. G. Dörr
  • W. Meier
  • S. S. Bielack
  • R. Rossi
  • P. Gutjahr
  • U. Schneider
  • O. Buurmann

There are no affiliations available

Personalised recommendations